Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient (male or non-pregnant female) must be \> 18 years of age.~* The patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board.~* Angiographically documented coronary artery disease defined as the presence of at least one 50% or greater stenosis of a major coronary artery.~* Stabilized post any prior ACS event (i.e., without ongoing ischemic rest pain, congestive heart failure, or malignant arrhythmias) for at least 3 months~* Fasting blood glucose 87-125 mg/dL~Exclusion Criteria:~* Age \<18 years~* Known hypersensitivity to metformin or rosiglitazone~* Renal insufficiency defined as calculated creatinine clearance (CrCl) \<40 mL/min using the following formula:~Men: CrCL (mL/min) = Weight (kg) x (140-age) 72 x serum creatinine (mg/dL) Women: 0.85 x the value calculated for men~* Pregnant and/or lactating women, and women of child bearing potential are excluded from this trial~* Co-morbidity such that the patient is not expected to survive \>2 years~* Current therapy with rosiglitazone or metformin~* PCI within the previous six months (other than for the qualifying event)~* Prior CABG within the previous two months, scheduled CABG, or a decision to perform CABG made prior to enrollment~* Overt diabetes mellitus (FBG\>126 or antidiabetic therapy)~* Any diagnosis of congestive heart failure~* Obstructive hepatobiliary disease or other significant hepatic disease (defined as the presence of at least one of the following: AST, ALT, GGT, total bilirubin, or alkaline phosphatase \>3x upper limit normal, not related to MI~* Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avandamet (Type: ACTIVE_COMPARATOR): AVANDAMET 2/500 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).